Inferra AIResearch Tools

Inferra AI / Company / IDXX

Idexx Laboratories

IDXX · Health Care

Last earnings Aug 4, 2026  ·  Next earnings Nov 2, 2026

Key results

Revenuequarter

11%

htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results · Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

revenues of $1,109 million for the second quarter of 2025, an increase of 11% as reported and 9% organic, driven by Companion Animal Group (&quot

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Second Quarter Performance Highlights Companion Animal Group (“CAG”) CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic, including 15% reported and 11% organic gains in International regions, and 6% reported and organic growth in the U.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

· IDEXX VetLab® consumables generated 15% reported and 14% organic revenue growth, with testing utilization gains across regions, benefits from recent product launches, and 10% growth in IDEXX's global premium instrument installed base.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

· Reference laboratory diagnostic and consulting services generated 6% reported and 5% organic revenue growth, including benefits from higher testing volumes and net price gains.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

· Rapid assay products revenues declined 3% on a reported and organic basis, with volumes impacted from the recent launch of the Catalyst® Pancreatic Lipase Test, which shifted some testing across modalities, offsetting net price benefits.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

CAG Diagnostics capital instrument revenues expanded 66% as reported and 62% on an organic basis led by record quarterly instrument placements.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Veterinary software, services and diagnostic imaging systems recurring and total revenues grew 9% on a reported and organic basis, led by continued momentum in cloud-based software attachments and installed base.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

AI analysis

Q2 2025 · reported Aug 4, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Headline figures

MetricQ2 2025Prior qtrYear ago
Revenue11%——

EX-99 · Aug 4, 2025

Guidance · company-stated

Direction: Raised

Revenue$4,205 million

“· Increases 2025 revenue guidance to $4,205 million - $4,280 million, an increase of $90 million or ~2% at midpoint, reflecting solid CAG Diagnostics recurring revenue performance, outlook for higher IDEXX inVue Dx™ instrument placements and revenues, and $70 million benefit of foreign exchange impacts versus prior estimates.”

Revenue

“· Updates 2025 EPS outlook to $12.40 - $12.76, reflecting $0.40 increase compared to prior guidance midpoint, supported by increased revenue and operating profit margin outlook, a lower effective tax rate, as well as benefits from updated foreign exchange impacts.”

Revenue

“2025 Growth and Financial Performance Outlook The Company is updating its full year revenue growth guidance range to $4,205 million - $4,280 million, or reported growth of 7.7% - 9.7%, an increase of $90 million at midpoint.”

Revenue

“The Company is increasing its outlook for organic revenue growth to 7% - 9%, an increase of 50 basis points at midpoint, reflecting the noted operational performance benefits.”

EPS

“IDEXX Announces Second Quarter Results August 4, 2025 Page 4 of 17 The Company updated its EPS outlook range to $12.40 - $12.76, incorporating a $0.40 increase at midpoint versus prior guidance, reflecting $0.11 benefit from operational performance, $0.09 from higher share-based compensation benefits, $0.02 net unfavorable adjustment to effective tax rate excluding share-based compensation benefits and including the release of a discrete tax reserve, and $0.22 in favorable adjustments to foreign exchange estimates.”

Classified from the release's primary full-year outlook statement.

Next earningsNov 2, 2026Verified from the company’s own announcement

Capital allocation

Capex$160M

To estimate projected 2025 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $160 million.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Idexx Laboratories Q2 2025 — htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results · Achieves second quarter revenue…

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “· Increases 2025 revenue guidance to $4,205 million - $4,280 million, an increase of $90 million or ~2% at midpoint, reflecting solid CAG Diagnostics recurring revenue performance, outlook for higher IDEXX inVue Dx™ instrument placements and revenues, and $70 million benefit of foreign exchange impacts versus prior estimates.”

Revenue: “· Updates 2025 EPS outlook to $12.40 - $12.76, reflecting $0.40 increase compared to prior guidance midpoint, supported by increased revenue and operating profit margin outlook, a lower effective tax rate, as well as benefits from updated foreign exchange impacts.”

Revenue: “2025 Growth and Financial Performance Outlook The Company is updating its full year revenue growth guidance range to $4,205 million - $4,280 million, or reported growth of 7.7% - 9.7%, an increase of $90 million at midpoint.”

Revenue: “The Company is increasing its outlook for organic revenue growth to 7% - 9%, an increase of 50 basis points at midpoint, reflecting the noted operational performance benefits.”

EPS: “IDEXX Announces Second Quarter Results August 4, 2025 Page 4 of 17 The Company updated its EPS outlook range to $12.40 - $12.76, incorporating a $0.40 increase at midpoint versus prior guidance, reflecting $0.11 benefit from operational performance, $0.09 from higher share-based compensation benefits, $0.02 net unfavorable adjustment to effective tax rate excluding share-based compensation benefits and including the release of a discrete tax reserve, and $0.22 in favorable adjustments to foreign exchange estimates.”

Revenue — Raised (“Increases”)
“· Increases 2025 revenue guidance to $4,205 million - $4,280 million, an increase of $90 million or ~2% at midpoint, reflecting solid CAG Diagnostics recurring revenue performance, outlook for higher IDEXX inVue Dx™ instrument placements and revenues, and $70 million benefit of foreign exchange impacts versus prior estimates.”

Revenue — Raised (“increase”)
“· Updates 2025 EPS outlook to $12.40 - $12.76, reflecting $0.40 increase compared to prior guidance midpoint, supported by increased revenue and operating profit margin outlook, a lower effective tax rate, as well as benefits from updated foreign exchange impacts.”

Revenue — Raised (“increase”)
“2025 Growth and Financial Performance Outlook The Company is updating its full year revenue growth guidance range to $4,205 million - $4,280 million, or reported growth of 7.7% - 9.7%, an increase of $90 million at midpoint.”

Revenue — Raised (“increasing”)
“The Company is increasing its outlook for organic revenue growth to 7% - 9%, an increase of 50 basis points at midpoint, reflecting the noted operational performance benefits.”

EPS — Raised (“increase”)
“IDEXX Announces Second Quarter Results August 4, 2025 Page 4 of 17 The Company updated its EPS outlook range to $12.40 - $12.76, incorporating a $0.40 increase at midpoint versus prior guidance, reflecting $0.11 benefit from operational performance, $0.09 from higher share-based compensation benefits, $0.02 net unfavorable adjustment to effective tax rate excluding share-based compensation benefits and including the release of a discrete tax reserve, and $0.22 in favorable adjustments to foreign exchange estimates.”

Classified from the release's primary full-year outlook statement.

Capital allocation

To estimate projected 2025 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $160 million.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Debt to Adjusted EBITDA (Leverage Ratios ) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Management believes that reporting Adjusted EBITDA, gross debt, and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net income or total debt reported in accordance with GAAP.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 .

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Securities and Exchange Commission Senior Note Agreements Note purchase agreements for the private placement of senior notes, referred to as senior notes or long-term debt SOFR The secured overnight financing rate as administered by the Federal Reserve Board of New York (or a successor administrator of the secured overnight financing rate) Term Loan Three-year, unsecured term loan in the principal amount of $250 million under the Credit Facility U.

SEC original ↗Idexx Laboratories — 10-Q Quarterly report10-QAug 4, 2026

Strategy & priorities

“Our innovation-driven strategy delivered robust global growth in the second quarter,” said Jay Mazelsky, President and Chief Executive Officer.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Our focus on helping veterinarians gain deeper diagnostic insights to inform patient care continues to drive customer loyalty and sets a solid foundation for sustained long-term growth.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Continued strong IDEXX commercial execution drove net customer gains and solid price realization while enabling our veterinary customers to increase diagnostic utilization, including benefits from recently launched IDEXX innovations, aiding expansion of CAG Diagnostics recurring revenues.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Gross margin of 62.6% increased 90 basis points as reported and 110 basis points on a comparable basis, supported by strong growth in IDEXX VetLab consumables revenue, Reference Labs productivity initiatives, and benefits from net price realization helping to offset inflationary impacts.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

The Company updated its full year reported operating margin outlook of 31.3% - 31.6%, bringing the projected full year comparable operating profit margin expansion to 50 - 80 basis points.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Risks & headwinds

· Delivers EPS of $3.63, an increase of 49% as reported, and 17% on a comparable basis, net of $0.56 EPS growth benefit from comparison to prior year period discrete litigation expense accrual, and including $0.07 benefit from a discrete tax reserve release.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Second quarter earnings per diluted share (“EPS”) were $3.63, an increase of 49% as reported and 17% on a comparable basis, net of $0.56 EPS growth benefit from comparison to a prior year period discrete litigation expense accrual.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Operating margin was 33.6% for the quarter, higher than the prior year period by 730 basis points as reported and by 130 basis points on a comparable basis, net of ~600 basis points impact from lapping the prior year period $61.5 million discrete litigation expense accrual.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Operating margin results reflect 9% operating expense decline as reported and 9% growth on a comparable basis, net of a 19% growth benefit from comparisons to the prior year period discrete litigation expense accrual.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

These risks and uncertainties include, among other things, the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in the corresponding sections of the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, as well as those described from time to time in the Company’s other filings with the U.

SEC original ↗Idexx Laboratories — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

61 documents

Earnings releases

21 documents

Presentations

0 documents

No presentations for Idexx Laboratories are held in this edition of the library.

Transcripts

0 documents

No transcripts for Idexx Laboratories are held in this edition of the library.

Mentioned by

2 companies

Other tracked companies whose held documents mention Idexx Laboratories by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.